Cargando…

PD-L1 expression levels on tumor cells affect their immunosuppressive activity

Programmed cell death 1 (PD-1) is an immuno-checkpoint receptor which is primarily expressed on T cells, monocytes, natural killer cells and macrophages. Programmed death-ligand 1 (PD-L1) is the primary ligand of PD-1 and is constitutively expressed on antigen presenting cells, mesenchymal stem cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Yang, Fang, You-Chen, Li, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781757/ https://www.ncbi.nlm.nih.gov/pubmed/31612048 http://dx.doi.org/10.3892/ol.2019.10903

Ejemplares similares

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
por: Pu, Yunzhou, et al.
Publicado: (2022)

Tumor-mediated immunosuppression and cytokine spreading affects the relation between EMT and PD-L1 status
por: Lems, Carlijn M., et al.
Publicado: (2023)

ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation
por: Monypenny, James, et al.
Publicado: (2018)

Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
por: Chen, Gang, et al.
Publicado: (2018)

Exosomal PD-L1 functions as an immunosuppressant to promote wound healing
por: Su, Dandan, et al.
Publicado: (2019)

The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor
por: Nie, Ding, et al.
Publicado: (2021)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
por: Mukherjee, Debayan, et al.
Publicado: (2023)

PD1/PD-L1 dependent immunosuppression by huiPS-derived cell population
por: Pini, Jonathan, et al.
Publicado: (2011)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
por: Scheffel, Thamiris Becker, et al.
Publicado: (2021)

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
por: Zhang, Yaqing, et al.
Publicado: (2017)

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression
por: Chen, Limo, et al.
Publicado: (2014)

Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1
por: Wen, Zhi-Fa, et al.
Publicado: (2018)

Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
por: Zhang, Jie, et al.
Publicado: (2015)

TIMELESS upregulates PD-L1 expression and exerts an immunosuppressive role in breast cancer
por: Dong, Xinrui, et al.
Publicado: (2023)

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
por: Zhang, Xiaozhen, et al.
Publicado: (2022)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

The Immunosuppressive Roles of PD-L1 during Influenza A Virus Infection
por: Ning, Hongya, et al.
Publicado: (2023)

Integrin-Linked Kinase Expression Characterizes the Immunosuppressive Tumor Microenvironment in Colorectal Cancer and Regulates PD-L1 Expression and Immune Cell Cytotoxicity
por: Almasabi, Saleh, et al.
Publicado: (2022)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
por: Teng, Meng‐Meng, et al.
Publicado: (2021)

ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation
por: Chen, Xiaozheng, et al.
Publicado: (2021)

Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer
por: Wang, Liping, et al.
Publicado: (2021)

PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)

PD-L1 Expression Affects Neoantigen Presentation
por: Okada, Masahiro, et al.
Publicado: (2020)

Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression
por: Sasi, Binu, et al.
Publicado: (2020)

PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity
por: Guo, Shuang, et al.
Publicado: (2022)

PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer
por: Kawasaki, Kento, et al.
Publicado: (2023)

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
por: Fan, Yangwei, et al.
Publicado: (2016)

EV PD-L1 Contributes to Immunosuppressive CD8(+) T Cells in Peripheral Blood of Pediatric Wilms Tumor
por: Zhang, Xiaoxue, et al.
Publicado: (2021)

PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
por: Zhu, Zhiyuan, et al.
Publicado: (2020)

Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer
por: Chen, Jing, et al.
Publicado: (2021)

Immunopotentiator Aikejia improves the therapeutic efficacy of PD-1/PD-L1 immunosuppressive pathway in CT26.WT cancer cell
por: Huang, Chaoqun, et al.
Publicado: (2019)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer
por: Li, Xuejiao, et al.
Publicado: (2022)

MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas
por: Wang, Qiang-Wei, et al.
Publicado: (2021)

A novel ternary heterostructure with dramatic SERS activity for evaluation of PD-L1 expression at the single-cell level
por: Feng, Enduo, et al.
Publicado: (2018)

IKBKE, a prognostic factor preferentially expressed in mesenchymal glioblastoma, modulates tumoral immunosuppression through the STAT3/PD‐L1 pathway
por: Yi, Li, et al.
Publicado: (2020)

PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread
por: Vesterinen, Tiina, et al.
Publicado: (2019)

CTHRC1 and PD-1/PD-L1 expression predicts tumor recurrence in prostate cancer
por: Zhou, Qing, et al.
Publicado: (2019)

CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
por: Song, Yue, et al.
Publicado: (2020)

STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia
por: Huang, Ze-Wei, et al.
Publicado: (2023)

Self-actuated biomimetic nanocomposites for photothermal therapy and PD-L1 immunosuppression
por: Li, Wenxin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f8cd76hpg754rm8r4oeht6dma0